Home » Stocks » BioPharmX

BioPharmX Corporation (BPMX)

May 19, 2020 - BPMX merged into TMBR
Stock Price: $0.510 USD 0.000 (0.00%)
Updated May 18, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 9.32M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 18.28M
EPS (ttm) -0.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day May 18, 2020
Last Price $0.510
Previous Close $0.510
Change ($) 0.000
Change (%) 0.00%
Day's Open -
Day's Range 0.456 - 0.525
Day's Volume 0
52-Week Range 0.250 - 1.180

More Stats

Market Cap 9.32M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 18.28M
Float 15.95M
EPS (basic) n/a
EPS (diluted) -0.75
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 91,024
Short Ratio 1.33
Short % of Float 0.57%
Beta 0.63
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 7.90
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -209.33%
ROE -2,020.23%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 0
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

Current: $0.510
Target: 12.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name BioPharmX Corporation
Country United States
Employees 3
CEO Steven M. Bosacki

Stock Information

Ticker Symbol BPMX
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: BPMX


BioPharmX Corporation, a specialty pharmaceutical company, develops products for the treatment of dermatologic conditions using its proprietary HyantX topical delivery system. Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase IIb clinical trials for the treatment of inflammatory lesions of acne; and BPX04, a topical antibiotic, which is in Phase IIb study for the treatment of inflammatory lesions of papulopustular rosacea. The company serves pharmaceutical companies, physician's practices, dermatologists, and general practitioners. BioPharmX Corporation is headquartered in Campbell, California.